Neon Lights Up First PD-1 Combo Study

The recent biotechnology startup Neon Therapeutics has quickly put its $55m Series A venture capital to work with plans to begin a Phase Ib clinical trial in 2016 for the company's lead immunotherapeutic candidate in combination with the Bristol-Myers Squibb Co. immuno-oncology star Opdivo (nivolumab).